82 Posts. 2 Drug Studies. 1 Mobile App Launch.
Here's what APOE4 carriers were doing inside Phoenix.
Key takeaways · TL;DR
In January the Phoenix Community logged 82 posts, launched a mobile app beta for iOS and Android with bloodwork and wearable tracking, analyzed the APOLLOE4 Phase 3 results for the APOE4-specific drug ALZ-801, and ran two device studies including the Neuronic ZenoWell and Sens.ai neurofeedback trials. Engaged members saw ApoB down 15 percent, HbA1c down 8 percent, and body fat down 12 percent over 3 to 6 months.
Definition
An investigational oral drug specifically developed for APOE4 carriers to slow or prevent Alzheimer disease progression.
ALZ-801 is one of the first Alzheimer therapeutics designed around APOE4-specific disease biology rather than the general Alzheimer population, and its Phase 3 APOLLOE4 trial is closely watched by the APOE4 community.
Phoenix Engaged Member Biomarker Changes
| Biomarker | Change over 3-6 months | Why it matters |
|---|---|---|
| ApoB | Down about 15 percent | Lower cardiovascular and Alzheimer risk |
| HbA1c | Down about 8 percent | Better blood sugar and insulin sensitivity |
| Body fat | Down about 12 percent | Lower inflammation and metabolic risk |
Hi Phoenix friend,
82 posts in 30 days.
That's how much happened inside the Phoenix Community this January. Real conversations. Real science. Real people fighting to outsmart Alzheimer's before it starts.
And you weren't in the room.
Here's a peek at what our members were doing while you were Googling "APOE4 supplements" for the hundredth time.
The Phoenix Mobile App Is Live
We launched the Phoenix Mobile App beta in January for both iOS and Android. A dedicated health hub built specifically for APOE4 carriers combining bloodwork, wearable data (integration with Apple Health and Google Health) and check-ins.
Combined with bloodwork, members log their interventions and daily life events (e.g.late dinner, alcohol, travel, supplements, etc.). Over time, this lets us derive insights like:
"Taking magnesium glycinate increased your sleep score by 15%"
"Taking ezetimibe reduced your LDL-c by 20%"
We aggregate this data at the community level to give personalized suggestions: "Based on similar members, here are the highest-impact levers for your goals."
This data also helps us identify hyper-responders for clinical trial recruitment.
Blood test tracking with AI-powered analysis. APOE4-specific biomarker ranges (not the generic ones your doctor uses). Supplement tracking with community ratings from people who share your genetics.
Members were uploading blood work, catching bugs, giving feedback, and watching their health data come to life. All in real time. All built by a founder who carries APOE4/4 himself.
One member uploaded blood tests three times by accident. Found a bug. Reported it. We fixed it. That's the beauty of building with your community, not for them.
A Potential APOE4 Drug Just Dropped Phase 3 Results
The APOLLOE4 Phase 3 findings came out. This is massive. ALZ-801 (valiltramiprosate) is one of the first drugs specifically targeting APOE4 carriers. Not the general Alzheimer's population. You.
Our members didn't just read the headline. They dissected the data together. They debated whether this could be the preventive drug APOE4 carriers have been waiting for. They weighed the evidence. They asked the hard questions most news articles skip.
This is what happens when 390+ motivated, science-literate people analyze a breakthrough in real time.
You can read a press release anywhere. You can't get that kind of peer analysis anywhere else.
Two Active Device Studies (Members Only)
While most people wonder if red light therapy or neurofeedback "actually works," our members are testing it.
The Neuronic ZenoWell Study wrapped up its active phase this month. Members enrolled, tracked outcomes, shared honest feedback (some loved it, some didn't feel it, some had side effects like dry mouth). That's how real science works. No hype. Just data.
The Sens.ai Neurofeedback Helmet Study launched. Another device, another structured experiment, another chance to be part of real-world evidence generation.
These aren't paid ads. These are medtech partnerships where Phoenix members get early access to devices and contribute to actual research. Companies come to us because our members are engaged, compliant, and already tracking their health data.
(Our first partnership enrolled 45 members in 5 days. The target was 30 in 2 weeks.)
Research Discussions That Actually Matter
Here's a sample of what our members were digging into this month:
Obicetrapib. A cholesterol drug with intriguing implications for APOE4 carriers. Members shared data, debated mechanisms, and connected it to their own lipid panels.
The Bredesen ReCODE Protocol. A new clinical trial paper came out. Instead of taking it at face value, our community did a critical read. What does the evidence actually show? Where are the gaps? That's the standard inside Phoenix.
CRISPR 2.0. More precise gene editing. More hope for neurological disorders. Members discussed what this means for APOE4 carriers specifically (and whether gene therapy could one day rewrite our risk entirely).
USC's New APOE4/4 Research Department. A major university just created an entire department to study people like us. Our members were discussing the implications before most news outlets covered it.
Rapamycin, Selegiline, Omega-3 (LPC-DHA), plant sterols, alpha-ketoglutarate. Not random supplement chatter. Structured discussions with citations, personal bloodwork, and honest reports of what's working and what's not.
The Stuff Nobody Talks About
Some of the most valuable conversations weren't about breakthroughs at all.
One member shared their frustration. Just... frustration. The weight of carrying this gene. The community showed up.
Another member's MOCA follow-up appointment got cancelled. Members helped navigate next steps.
Someone asked about anesthesia risks for APOE4 carriers. (Bet your doctor never mentioned that.)
Gas stoves. Tattoo safety. Whether pink noise actually helps sleep (a new study says maybe not). These are the niche, APOE4-specific questions you can't Google effectively. But you can ask 320+ people who live this every day.
A Community That Moves Together
January kicked off with our monthly Goals and Accountability posts. Members set targets. Shared progress. Held each other to it.
Our members don't just consume content. They recruit new members, push for pharmaceutical partnerships, share research, and openly track their health journeys with each other.
Average biomarker improvements for engaged members over 3-6 months: ApoB down 15%. HbA1c down 8%. Body fat down 12%.
Those aren't hypothetical. Those are our members' actual numbers.
So Why Aren't You Here Yet?
Look. You can keep piecing together Alzheimer's prevention advice from Reddit threads, random podcasts, and Dr. Google.
Or you can join the only community built specifically for APOE4 carriers. By an APOE4/4 carrier. With real data, real experiments, real partnerships, and real people who understand exactly what you're going through.
January alone had 82 posts of science, support, and action.
February is already underway.
The question isn't whether you can afford to join. It's whether you can afford to keep missing this.
Most Newsletters? One-way street.
How boring…
This is the Phoenix Community. So let's make it a two-way street.
Got a question? Feedback?
Hit reply. I read every single one.
The Phoenix Community is a private, science-driven membership for APOE4 carriers and anyone serious about Alzheimer's prevention. Founded by Dr. Kevin Tran (APOE4/4), we combine structured health experiments, expert access, pharmaceutical partnerships, and peer accountability to help members take control of their cognitive future.
